These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2738187)

  • 1. Prolonged fever without extrapyramidal symptoms during neuroleptic treatment.
    Keshavan MS; Kambhampati RK
    J Clin Psychopharmacol; 1989 Jun; 9(3):230-1. PubMed ID: 2738187
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine.
    Granato JE; Stern BJ; Ringel A; Karim AH; Krumholz A; Coyle J; Adler S
    Ann Neurol; 1983 Jul; 14(1):89-90. PubMed ID: 6614876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate.
    Gelenberg AJ; Doller JC; Schooler NR; Mieske M; Severe J; Mandel MR
    Am J Psychiatry; 1979 Feb; 136(2):217-9. PubMed ID: 367182
    [No Abstract]   [Full Text] [Related]  

  • 4. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
    Chouinard G; Annable L; Ross-Chouinard A
    Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
    [No Abstract]   [Full Text] [Related]  

  • 5. Extrapyramidal reaction to fluphenazine potentiated by thyrotoxicosis.
    Witschy JK; Redmond FC
    Am J Psychiatry; 1981 Feb; 138(2):246-7. PubMed ID: 7457650
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-acting formulation leading to severe long-term adverse effects: a case report of fluphenazine and persistent extrapyramidal symptoms.
    Omi T; Mitsui Y; Matsunaga H
    J Clin Pharm Ther; 2018 Feb; 43(1):117-120. PubMed ID: 28718220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient.
    Aruna AS; Murungi JH
    Ann Pharmacother; 2005 Jun; 39(6):1131-5. PubMed ID: 15840734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first-episode schizophrenic patients.
    Koreen AR; Lieberman J; Alvir J; Chakos M; Loebel A; Cooper T; Kane J
    Am J Psychiatry; 1994 Jan; 151(1):35-9. PubMed ID: 8267132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiating effect of fluphenazine decanoate and risperidone on development of neuroleptic malignant syndrome.
    Liu PY; Wu PC; Chen CY; Chen YC
    Gen Hosp Psychiatry; 2011; 33(1):84.e5-7. PubMed ID: 21353143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic significance of selected side effects occurring in the course of prolonged-action fluphenazine treatment].
    Koślacz A; Popkowska N; Kulesza E; Lysikowska-Prokop L; Marmurowska-Michalowska H; Perzyński J
    Psychiatr Pol; 1977; 11(2):159-64. PubMed ID: 887674
    [No Abstract]   [Full Text] [Related]  

  • 11. The use of fluphenazine enanthate in psychotic patients.
    Routsonis KG; Photiadis H
    Curr Ther Res Clin Exp; 1973 Mar; 15(3):92-6. PubMed ID: 4196232
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate.
    Kane J; Quitkin F; Rifkin A; Klein DF
    Am J Psychiatry; 1978 Dec; 135(12):1539-42. PubMed ID: 717574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An unusual presentation of neuroleptic malignant syndrome.
    Basu J
    J Indian Med Assoc; 1991 Jan; 89(1):16. PubMed ID: 2051035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rigidity, hyperpyrexia and coma following fluphenazine enanthate.
    Meltzer HY
    Psychopharmacologia; 1973; 29(4):337-46. PubMed ID: 4707025
    [No Abstract]   [Full Text] [Related]  

  • 15. Patients at risk of developing severe side effects from depot fluphenazine treatment.
    Blum A
    Am J Psychiatry; 1980 Feb; 137(2):254-5. PubMed ID: 7352591
    [No Abstract]   [Full Text] [Related]  

  • 16. Extrapyramidal symptoms in the course of fluphenazine treatment.
    Bastecký J; Vinar O; Taussigová D
    Act Nerv Super (Praha); 1972; 14(2):97-9. PubMed ID: 5040184
    [No Abstract]   [Full Text] [Related]  

  • 17. Depressive and extrapyramidal symptoms and clinical effects: a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out-patients.
    Knights A; Okasha MS; Salih MA; Hirsch SR
    Br J Psychiatry; 1979 Dec; 135():515-23. PubMed ID: 394794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of the neuroleptic malignant syndrome with bromocriptine.
    Dhib-Jalbut S; Hesselbrock R; Brott T; Silbergeld D
    JAMA; 1983 Jul 22-29; 250(4):484-5. PubMed ID: 6134848
    [No Abstract]   [Full Text] [Related]  

  • 19. Fluphenazine decanoate, oral fluphenazine, and placebo in the treatment of remitted schizophrenics. II. Rating scale data [proceedings].
    Rifkin A; Quitkin F; Kane J; Klein DF
    Psychopharmacol Bull; 1977 Apr; 13(2):49-50. PubMed ID: 323910
    [No Abstract]   [Full Text] [Related]  

  • 20. Neuroleptic malignant syndrome presenting without initial fever: a case report.
    Totten VY; Hirschenstein E; Hew P
    J Emerg Med; 1994; 12(1):43-7. PubMed ID: 8163804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.